Research
Hormonal
Semaglutide 2.4 mg/week significantly reduces the incidence of new-onset type 2 diabetes and prediabetes in overweight or obese adults without diabetes.
For overweight or obese individuals without diabetes, semaglutide 2.4 mg/week reduces the risk of developing type 2 diabetes by 73% and prediabetes by 67% compared to placebo.
StrongSupportsVERY_HIGH confidence
The incidences of diabetes and prediabetes were reduced by 73% and 67%, respectively with semaglutide.
Why this rating
Based on the SELECT trial, a large, randomized, placebo-controlled trial.
Source
Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events
Nasser Mikhail et al. · Annals of Cardiovascular Diseases · 2024
narrative_review · n=17604Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →